Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.53 |
| ▸ | RELA | Q04206 | 5/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078254 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL2137399 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4274302 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL12951153 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4951462 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605621 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5270119 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605147 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL15215795 | 0.87 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL19337828 | 0.86 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1763351-B9 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2875023-B1 | OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-05 | — | — | EP | disclosed |
| EP-1763351-B1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE HOLDINGS CORP (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9024017-B2 | Octahydro-cyclopentapyrrolyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-05 | — | — | US | disclosed |
| US-20140024646-A1 | OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563582-B2 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6252112-B1 | MIBCROBIAL HYDROLYSIS OF THE TITLE COMPOUND DERIVATIVE USING ENZYME HAVING N-ACETYLAMINO-ALCOHOL HYDROLASE OR PENICILLIN G ACYLASE ACTIVITY WITH SUBSEQUENT ACYLATION | LONZA A.G., (CH) | 2001-06-26 | — | — | US | disclosed |
| WO-2001001569-A2 | PROCESS FOR PREPARING (-)-(1S,4R) N-PROTECTED 4-AMINO-2-CYCLOPENTENE-1-CARBOXYLATE ESTERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6156893-A | Process for the preparation of (1S,4R)- or (1R,4S)- 4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol | LONZA A.G. (CH) | 2000-12-05 | — | — | US | disclosed |
| US-6147254-A | Process for resolving mixtures of carbocyclic stereoisomers | GLAXO WELLCOME INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6137007-A | CHEMICAL INTERMEDIATES FOR NUCLEOSIDE, 4-2-(AMINO-6-CHLORO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL, WHICH IS AN INTERMEDIATE FOR 6-(CYCLOPROPYLAMINO)-DERIVATIVE | LONZA AG (CH) | 2000-10-24 | — | — | US | disclosed |
| EP-0946496-A2 | PROCESS FOR RESOLVING MIXTURES OF CARBOCYCLIC STEREOISOMERS | GLAXO GROUP LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| CN-1201794-A | Process for the preparation of (1S,4R) -or (1R,4S) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol or salts thereof | LONZA AG (CH) | 1998-12-16 | — | — | CN | disclosed |
| WO-1998024741-A2 | PROCESS FOR RESOLVING MIXTURES OF CARBOCYCLIC STEREOISOMERS | GLAXO GROUP LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | NFKB1 2513/4885NFKB2 3299/4885RELA 2806/4885 |
| US-20140024646-A1 | OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | NFKB1 594/4885NFKB2 587/4885RELA 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.